A number of other brokerages also recently issued reports on SNSS. HC Wainwright reaffirmed a hold rating and issued a $2.00 price target on shares of Sunesis Pharmaceuticals in a report on Monday, June 17th. Zacks Investment Research raised Sunesis Pharmaceuticals from a hold rating to a buy rating and set a $1.25 price target for the company in a report on Wednesday, May 15th. Finally, Cowen reaffirmed a hold rating on shares of Sunesis Pharmaceuticals in a report on Sunday, June 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $3.08.
Shares of Sunesis Pharmaceuticals stock traded down $0.04 on Thursday, reaching $0.76. 26,115 shares of the company were exchanged, compared to its average volume of 1,339,055. Sunesis Pharmaceuticals has a 1-year low of $0.20 and a 1-year high of $2.60. The company has a market capitalization of $55.12 million, a P/E ratio of -1.01 and a beta of 2.79. The stock’s 50 day moving average is $0.76.
In other news, major shareholder Aisling Capital Iv, Lp acquired 2,500,000 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was acquired at an average cost of $0.60 per share, with a total value of $1,500,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.22% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in SNSS. Algert Global LLC purchased a new position in Sunesis Pharmaceuticals in the first quarter worth $25,000. Fosun International Ltd purchased a new position in Sunesis Pharmaceuticals in the first quarter worth $863,000. Finally, Aisling Capital Management LP raised its position in Sunesis Pharmaceuticals by 192.3% in the first quarter. Aisling Capital Management LP now owns 7,600,000 shares of the biopharmaceutical company’s stock worth $9,234,000 after acquiring an additional 5,000,000 shares in the last quarter. Institutional investors and hedge funds own 43.08% of the company’s stock.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Read More: How to calculate compound interest
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.